Missed opportunities for vaccination among children aged 0–23 months visiting health facilities in a southwest State of Nigeria, December 2019

PLoS One
http://www.plosone.org/
[Accessed 28 Aug 2021]

 

Missed opportunities for vaccination among children aged 0–23 months visiting health facilities in a southwest State of Nigeria, December 2019
Akinola Ayoola Fatiregun, Laura Nic Lochlainn, Lassané Kaboré, Modupeola Dosumu, Elvis Isere, Itse Olaoye, Francis Adegoke Akanbiemu, Yetunde Olagbuji, Rosemary Onyibe, Kofi Boateng, Richard Banda, Fiona Braka
Research Article | published 27 Aug 2021 PLOS ONE
https://doi.org/10.1371/journal.pone.0252798

The background occurrence of selected clinical conditions prior to the start of an extensive national vaccination program in Japan

PLoS One
http://www.plosone.org/
[Accessed 28 Aug 2021]

 

The background occurrence of selected clinical conditions prior to the start of an extensive national vaccination program in Japan
Tomotaka Sobue, Haruhisa Fukuda, Tetsuya Matsumoto, Bennett Lee, Shuhei Ito, Satoshi Iwata
Research Article | published 26 Aug 2021 PLOS ONE
https://doi.org/10.1371/journal.pone.0256379

Identifying the determinants of COVID-19 preventative behaviors and vaccine intentions among South Carolina residents

PLoS One
http://www.plosone.org/
[Accessed 28 Aug 2021]

 

Identifying the determinants of COVID-19 preventative behaviors and vaccine intentions among South Carolina residents
Justin Travis, Scott Harris, Tina Fadel, Ginny Webb
Research Article | published 25 Aug 2021 PLOS ONE
https://doi.org/10.1371/journal.pone.0256178

Exploring the behavioral determinants of COVID-19 vaccine acceptance among an urban population in Bangladesh: Implications for behavior change interventions

PLoS One
http://www.plosone.org/
[Accessed 28 Aug 2021]

 

Exploring the behavioral determinants of COVID-19 vaccine acceptance among an urban population in Bangladesh: Implications for behavior change interventions
Md. Abul Kalam, Thomas P. Davis Jr., Shahanaj Shano, Md. Nasir Uddin, Md. Ariful Islam, Robert Kanwagi, Ariful Islam, Mohammad Mahmudul Hassan, Heidi J. Larson
Research Article | published 23 Aug 2021 PLOS ONE
https://doi.org/10.1371/journal.pone.0256496

Socioeconomic privilege and political ideology are associated with racial disparity in COVID-19 vaccination

PNAS – Proceedings of the National Academy of Sciences of the United States of America
August 17, 2021; vol. 118 no. 33
https://www.pnas.org/content/118/33

 

Brief Reports
Open Access
Socioeconomic privilege and political ideology are associated with racial disparity in COVID-19 vaccination
Ritu Agarwal, Michelle Dugas, Jui Ramaprasad, Junjie Luo, Gujie Li, and Guodong (Gordon) Gao
PNAS August 17, 2021 118 (33) e2107873118; https://doi.org/10.1073/pnas.2107873118

Tetanus vaccination in pregnant women: a systematic review and meta-analysis of the global literature

Public Health
Volume 196 Pages A1-A2, e1-e4, 1-228 (July 2021)
https://www.sciencedirect.com/journal/public-health/vol/196/suppl/C

 

Review article Abstract only
Tetanus vaccination in pregnant women: a systematic review and meta-analysis of the global literature
A.P.V. Faria, T.P.R. da Silva, C.K. Duarte, L.L. Mendes, … F.P. Matozinhos
Pages 43-51

The efficacy of vaccination to prevent human papilloma viruses infection at anal and oral: a systematic review and meta-analysis

Public Health
Volume 196 Pages A1-A2, e1-e4, 1-228 (July 2021)
https://www.sciencedirect.com/journal/public-health/vol/196/suppl/C

 

Review article Open access
The efficacy of vaccination to prevent human papilloma viruses infection at anal and oral: a systematic review and meta-analysis
Jiye Zhang, Zhilin Qin, Chaoyong Lou, Jing Huang, Youfu Xiong
Pages 165-171

Early childhood vaccination coverage and timeliness by macro-area of origin in children born to foreign women residing in Italy

Public Health
Volume 196 Pages A1-A2, e1-e4, 1-228 (July 2021)
https://www.sciencedirect.com/journal/public-health/vol/196/suppl/C

 

Research article Abstract only
Early childhood vaccination coverage and timeliness by macro-area of origin in children born to foreign women residing in Italy
T. Spadea, V. Fano, C. Piovesan, R. Rusciani, … M. Fabiani
Pages 138-145

Caregivers’ Sources of Information About Immunization as Predictors of Delayed Childhood Vaccinations in Saudi Arabia During the COVID-19 Pandemic: A Cross-Sectional Questionnaire Study

Risk Management and Healthcare Policy
https://www.dovepress.com/risk-management-and-healthcare-policy-archive56
[Accessed 28 Aug 2021]

 

Original Research
Caregivers’ Sources of Information About Immunization as Predictors of Delayed Childhood Vaccinations in Saudi Arabia During the COVID-19 Pandemic: A Cross-Sectional Questionnaire Study
Baghdadi LR, Hassounah MM, Younis A, Al Suwaidan HI, Al Khalifah R
Risk Management and Healthcare Policy 2021, 14:3541-3550
Published Date: 24 August 2021

Colleges must require vaccination

Science
27 August 2021 Vol 373, Issue 6558
http://www.sciencemag.org/current.dtl

 

Editorial
Colleges must require vaccination
By Michael A. McRobbie
Science27 Aug 2021 :
Summary
This week, the US Food and Drug Administration (FDA) granted full approval to the Pfizer-BioNTech coronavirus vaccine for individuals 16 years and older. This milestone decision, the first full approval of a vaccine for COVID-19, will almost certainly clear a path for businesses, hospitals, and government agencies that have not already done so to adopt vaccine mandates for their employees. For colleges and universities that have been on the fence about requiring the vaccine, the FDA’s decision may be especially welcome news.

Unethical? Unnecessary? The booster debate intensifies

Science
27 August 2021 Vol 373, Issue 6558
http://www.sciencemag.org/current.dtl

 

In Depth
Unethical? Unnecessary? The booster debate intensifies
By Gretchen Vogel
Science27 Aug 2021 : 949-950 Restricted Access
As United States reveals its plan to offer an extra dose of COVID-19 vaccine, equity and scientific questions abound.
Summary
As the extraordinarily infectious Delta variant of SARS-CoV-2 continues to spread around the world, vaccines’ powers are showing their limits. Although they are still extremely effective at preventing severe COVID-19, the tantalizing hope that the shots could block almost all infections—and squelch transmission—has evaporated. That has upended return to office and school plans, threatened economic recoveries, and spurred fresh political rows over mask and vaccination mandates. Now, amid new studies hinting that vaccine-induced immunity may be waning, policymakers and scientists are debating whether widespread booster shots could help or getting shots into the arms of the unvaccinated should remain the top priority. And many people wonder whether one booster will suffice or periodic COVID-19 vaccination will become the new normal, as it is for influenza.

Effectiveness of hepatitis B vaccination in chronic HCV patients after successful generic direct acting antiviral therapy: significance of isolated hepatitis B core antibodies

Tropical Medicine & International Health
Volume 26, Issue 8 Pages: i-iv, 839-1013 August 2021
https://onlinelibrary.wiley.com/toc/13653156/current

 

Original Research Papers
Effectiveness of hepatitis B vaccination in chronic HCV patients after successful generic direct acting antiviral therapy: significance of isolated hepatitis B core antibodies
Ekram W. Abd El-Wahab, Mohammed Metwally, Nesma Lotfy
Pages: 882-894
First Published: 15 April 2021

Systematic review of the costs for vaccinators to reach vaccination sites: Incremental costs of reaching hard-to-reach populations

Vaccine
Volume 39, Issue 33 Pages 4571-4758 (30 July 2021)
https://www.sciencedirect.com/journal/vaccine/vol/39/issue/33

 

Review article Abstract only
Systematic review of the costs for vaccinators to reach vaccination sites: Incremental costs of reaching hard-to-reach populations
Sachiko Ozawa, Tatenda T. Yemeke, Elizabeth Mitgang, Patrick T. Wedlock, … Bruce Y. Lee
Pages 4598-4610

Estimating the economic burden of pneumococcal meningitis and pneumonia in northern Ghana in the African meningitis belt post-PCV13 introduction

Vaccine
Volume 39, Issue 33 Pages 4571-4758 (30 July 2021)
https://www.sciencedirect.com/journal/vaccine/vol/39/issue/33

 

Review article Abstract only
Estimating the economic burden of pneumococcal meningitis and pneumonia in northern Ghana in the African meningitis belt post-PCV13 introduction
Miwako Kobayashi, Abass Abdul-Karim, Jennifer L. Milucky, Adam Zakariah, … Fernanda C. Lessa
Pages 4685-4699

Predictors of Willingness to Receive COVID-19 Vaccine: Cross-Sectional Study of Palestinian Dental Students

Vaccines
https://www.mdpi.com/journal/vaccines
[Accessed 28 Aug 2021]

 

Open Access Article
Predictors of Willingness to Receive COVID-19 Vaccine: Cross-Sectional Study of Palestinian Dental Students
by Elham Kateeb et al
Vaccines 2021, 9(9), 954; https://doi.org/10.3390/vaccines9090954 (registering DOI) – 26 Aug 2021
Abstract
The overarching aim of this study was to assess the predictors related to the willingness of Palestinian dental students to receive the COVID-19 vaccine when it becomes available. A cross-sectional study was conducted among a universal sample of dental students in the Palestinian […]

Willingness to Get the COVID-19 Vaccine among Residents of Slum Settlements

Vaccines
https://www.mdpi.com/journal/vaccines
[Accessed 28 Aug 2021]

 

Open Access Communication
Willingness to Get the COVID-19 Vaccine among Residents of Slum Settlements
by Juan P. Aguilar Ticona et al
Vaccines 2021, 9(9), 951; https://doi.org/10.3390/vaccines9090951 (registering DOI) – 26 Aug 2021
Abstract
Slum residents are more vulnerable to COVID-19 infection. Without a specific treatment, vaccination became the main strategy against COVID-19. In this study, we determined the rate and factors associated with the willingness to get vaccinated against COVID-19 among slum residents and their main […] R

medRxiv

medRxiv
medRxiv is a free online archive and distribution server for complete but unpublished manuscripts (preprints) in the medical, clinical, and related health sciences. Preprints are preliminary reports of work that have not been certified by peer review. They should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information. medRxiv is for the distribution of preprints – complete but unpublished manuscripts – that describe human health research conducted, analyzed, and interpreted according to scientific principles…
https://www.medrxiv.org/content/about-medrxiv
[Accessed 28 Aug 2021]

Selected Content
Effectiveness of vaccination against symptomatic and asymptomatic SARS-CoV-2 infection: a systematic review and meta-analysis
Angela Meggiolaro, Monica Sane Schepisi, George Nikolaidis, Daniele Mipatrini, Andrea Siddu, Giovanni Rezza
medRxiv 2021.08.25.21262529; doi: https://doi.org/10.1101/2021.08.25.21262529

Estimating the global demand curve for a leishmaniasis vaccine: a generalisable approach based on global burden of disease estimates
Sakshi Mohan, Paul Revill, Stefano Malvolti, Melissa Malhame, Mark Sculpher, Paul M Kaye
medRxiv 2021.08.26.21262379; doi: https://doi.org/10.1101/2021.08.26.21262379

Willingness and influential factors of parents to vaccinate their children against the COVID-19: a systematic review and meta-analysis
Petros Galanis, Irene Vraka, Olga Siskou, Olympia Konstantakopoulou, Aglaia Katsiroumpa, Daphne Kaitelidou
medRxiv 2021.08.25.21262586; doi: https://doi.org/10.1101/2021.08.25.21262586

Democratic governance and excess mortality during the COVID-19 pandemic
Vageesh Jain, Jonathan Clarke, Thomas Beaney
medRxiv 2021.08.25.21262614; doi: https://doi.org/10.1101/2021.08.25.21262614

Prioritizing COVID-19 vaccination efforts and dose allocation within Madagascar
Fidisoa Rasambainarivo, Tanjona Ramiadantsoa, Antso Raherinandrasana, Santatra Randrianarisoa, Benjamin L Rice, Michelle V. Evans, Benjamin ROCHE, Fidiniaina Mamy Randriatsrafara, Amy Wesolowski, C. Jessica E. Metcalf
medRxiv 2021.08.23.21262463; doi: https://doi.org/10.1101/2021.08.23.21262463

Comparing SARS-CoV-2 natural immunity to vaccine-induced immunity: reinfections versus breakthrough infections
Sivan Gazit, Roei Shlezinger, Galit Perez, Roni Lotan, Asaf Peretz, Amir Ben-Tov, Dani Cohen, Khitam Muhsen, Gabriel Chodick, Tal Patalon
medRxiv 2021.08.24.21262415; doi: https://doi.org/10.1101/2021.08.24.21262415

Comparing SARS-CoV-2 natural immunity to vaccine-induced immunity: reinfections versus breakthrough infections
Sivan Gazit, Roei Shlezinger, Galit Perez, Roni Lotan, Asaf Peretz, Amir Ben-Tov, Dani Cohen, Khitam Muhsen, Gabriel Chodick, Tal Patalon
medRxiv 2021.08.24.21262415; doi: https://doi.org/10.1101/2021.08.24.21262415

Shedding of Infectious SARS-CoV-2 Despite Vaccination
Kasen K. Riemersma, Brittany E. Grogan, Amanda Kita-Yarbro, Peter J. Halfmann, Hannah E. Segaloff, Anna Kocharian, Kelsey R. Florek, Ryan Westergaard, Allen Bateman, Gunnar E. Jeppson, Yoshihiro Kawaoka, David H. O’Connor, Thomas C. Friedrich, Katarina M. Grande
medRxiv 2021.07.31.21261387; doi: https://doi.org/10.1101/2021.07.31.21261387

COVID-19 related messaging, beliefs, information sources, and mitigation behaviors in Virginia: A cross-sectional survey in the summer of 2020
Rachel A. Silverman, Danielle Short, Sophie Wenzel, Mary Ann Friesen, Natalie E. Cook
medRxiv 2021.08.18.21262217; doi: https://doi.org/10.1101/2021.08.18.21262217

Think Tanks et al

Think Tanks et al
 
 
Brookings [to 28 Aug 2021]
http://www.brookings.edu/
[No new digest content identified]

 
 
Center for Global Development [to 28 Aug 2021]
http://www.cgdev.org/page/press-center
The Next Pandemic Could Come Soon and Be Deadlier
August 25, 2021
Last month, CGD hosted an event on predicting the frequency and scale of future pandemics to discuss what’s to come after the COVID-19 pandemic and the critical task of preparing for future outbreak probabilities. This blog highlights three key takeaways from the event.
Eleni Smitham and Amanda Glassman
 
 
Chatham House [to 28 Aug 2021]
https://www.chathamhouse.org/
Accessed 28 Aug 2021
[No new digest content identified]

 
 

CSIS
https://www.csis.org/
Accessed 28 Aug 2021
Blog Post
How India Can Help Vaccinate the World
August 23, 2021

Podcast Episode
Dr. Anthony Fauci: Tour d’Horizon Aug 2, 2021
August 23, 2021 | By J. Stephen Morrison

 
 

Kaiser Family Foundation
https://www.kff.org/search/?post_type=press-release
August 27, 2021 News Release
Two New KFF Reports Take a Closer Look at the COVID-19 Pandemic and the LGBT Community, From the Impact on Mental Health to Vaccination Status
Two new KFF reports provide new and updated data on the experiences of lesbian, gay, bisexual and transgender (LGBT) people during the COVID-19 pandemic, featuring data showing the impact on mental health and COVID-19 Vaccine Monitor data on vaccine uptake within the community. The two reports add important context to…
 
 
Urban Institute [to 28 Aug 2021]
https://www.urban.org/publications
Publications
[No new digest content identified]

Vaccines and Global Health: The Week in Review :: 21 August 2021

Vaccines and Global Health: The Week in Review is a weekly digest  summarizing news, events, announcements, peer-reviewed articles and research in the global vaccine ethics and policy space. Content is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage. You are viewing the blog version of our weekly digest, typically comprised of between 30 and 40 posts below all dated with the current issue date

.– Request an Email Summary: Vaccines and Global Health : The Week in Review is published as a single email summary, scheduled for release each Saturday evening before midnight (EDT in the U.S.). If you would like to receive the email version, please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.

– pdf version A pdf of the current issue is available here: 

– blog edition: comprised of the approx. 35+ entries posted below.

– Twitter:  Readers can also follow developments on twitter: @vaxethicspolicy.
.
– Links:  We endeavor to test each link as we incorporate it into any post, but recognize that some links may become “stale” as publications and websites reorganize content over time. We apologize in advance for any links that may not be operative. We believe the contextual information in a given post should allow retrieval, but please contact us as above for assistance if necessary.

Support this knowledge-sharing service: Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click here to donate and thank you in advance for your contribution.

.
David R. Curry, MS
Executive Director
Center for Vaccine Ethics and Policy

COVID

Milestones :: Perspectives :: Research

 

COVID

 

Editor’s Note:
As is obvious to all, the sheer volume of strategic announcements, regulatory actions, country program decisions, commentary, and, indeed, misinformation around COVID response continues at extraordinary levels. Our weekly digest strives to present a coherent and comprehensive snapshot, but cannot be exhaustive, If you recognize a missed strategic development, a new source of rigorous analysis, or an insight/commentary that would benefit our common understanding, please advise me…we will review all suggestions and consider for inclusion in a subsequent edition: david.r.curry@ge2p2global.org

We are seeking access to modelling which engages scenarios and articulates imperatives around a pandemic end-game through at least a 2025 horizon. We assess that WHO must be conducting or contracting for such modeling – or should recognize an imperative to be doing so in its global health governance role. If we have missed such modeling in progress, we would be delighted to be advised of it and will include it in our coverage.

ACT-Accelerator launches urgent US$ 7.7 billion appeal to stem surge of dangerous variants and save lives everywhere

Milestones :: Perspectives :: Research

ACT-Accelerator launches urgent US$ 7.7 billion appeal to stem surge of dangerous variants and save lives everywhere
16 August 2021 WHO News release
Delta variant on path to become dominant strain worldwide as surge in the highly transmissible variant increases urgency for vaccinating large numbers of vulnerable people
Rising infection rates resulting in increased hospitalizations are overwhelming health systems and leaving many countries in urgent need of life-saving oxygen
Testing rates in much of the world is too low, especially low- and lower-middle-income countries [1] – leaving much of the world blind to how the disease is evolving and vulnerable to new variants
Funding the Rapid ACT-Accelerator Delta Response (RADAR) urgent appeal for US $7.7 billion would enable: significantly increased testing and better surveillance to detect and protect against new variants; more oxygen to treat the seriously ill and save lives; vital personal protective equipment (PPE) to protect health workers; the rolling out of emergency response and delivery support for the effective delivery and deployment of COVID-19 tools, including in humanitarian contexts; and continued research and development (R&D) so that tools remain effective
The US$ 7.7 billion is not an additional funding need but is part of the ACT-Accelerator’s overall 2021 budget, which is needed urgently within the next four months

With more COVID-19 cases reported in the first five months of 2021 than in the whole of 2020, the world is still in the acute phase of the pandemic – despite high vaccination rates in some countries protecting populations from severe disease and death. Inadequate testing and low vaccination rates are exacerbating disease transmission and overwhelming local health systems, while leaving the whole world vulnerable to new variants.

Many countries are experiencing new waves of infections – and while many high-income countries and some upper-middle-income countries have implemented widespread vaccinations, put more robust testing systems in place, and made treatments increasingly available – many low- and lower-middle-income countries are struggling to access these vital tools due to a lack of funds and supplies. Investing in the ACT-Accelerator to make tools available to everyone, everywhere, will benefit all countries through a more globally inclusive and coordinated response.

While four variants of concern currently dominate the epidemiology, there are fears that new, and possibly more dangerous, variants of concern may emerge.

With hard-won gains of the last three months at risk, the ACT-Accelerator has mounted a US$ 7.7 billion appeal, the Rapid ACT-Accelerator Delta Response (RADAR), to urgently:
Scale up testing: US$2.4 billion to put all low- and lower-middle-income countries on track towards a ten-fold increase in COVID-19 testing and ensure all countries get up to satisfactory testing levels. This will significantly enhance local and global understanding of the changing disease epidemiology and emerging variants of concern, inform the appropriate application of public health and social measures and break chains of transmission.

Maintain R&D efforts to stay ahead of the virus: US$ 1 billion for ongoing R&D, enable further market shaping and manufacturing, technical assistance and demand generation to ensure that tests, treatments and vaccines remain effective against the Delta variant and other emerging variants, and that they are accessible and affordable where they are needed.

Address acute oxygen needs to save lives:  US$ 1.2 billion to rapidly address acute oxygen needs to treat the seriously ill and control the exponential death surges caused by the Delta variant.

Rollout of tools: US$ 1.4 billion to help countries identify and address key bottlenecks for the effective deployment and use of all COVID-19 tools. As supply of COVID-19 vaccines ramps up in the coming months, flexible funding will be essential to help fill on-the-ground delivery gaps.

Protect frontline healthcare workers: US$ 1.7 billion to provide two million essential healthcare workers with enough basic PPE to keep them safe while they care for the sick, prevent the collapse of health systems where the health workforce is already understaffed and overstretched, and prevent further spread of COVID-19.

In addition to the US$ 7.7 billion appeal, there is an opportunity to reserve the supply of vaccines through exercising options in the fourth quarter of 2021 for 760 million doses of vaccine to be available in mid-2022 beyond the fully subsidised doses that COVAX will deliver up to the end of Q1 2022.  Commitments to reserve these vaccine options in the last quarter of the year for delivery in the middle of 2022 can be made to Gavi/COVAX, as part of the ACT-A network of agencies.

Reserve vaccines: Reserve supply of 760 million doses of vaccine by exercising options in the final quarter this year to ensure there is continued supply available to make deliveries into 2022. Reserving doses requires contingent capital; on delivery these 760m doses will cost an additional US$ 3.8 billion…

Multilateral Leaders Task Force on COVID-19 [IMF, World Bank Group, WHO, WTO]

Milestones :: Perspectives :: Research

 

Multilateral Leaders Task Force on COVID-19 [IMF, World Bank Group, WHO, WTO]
A joint initiative from the International Monetary Fund, World Bank Group, World Health Organization, and World Trade Organization to accelerate access to COVID-19 vaccines, therapeutics and diagnostics by leveraging multilateral finance and trade solutions, particularly in low- and middle-income countries.
Data to help track, coordinate, and advance delivery of COVID-19 health tools to developing countries and to mobilize relevant stakeholders and national leaders to remove critical roadblocks – in support of the priorities set out by the WBG, IMF, WHO, and WTO.

Website accessed 21 Aug 21: https://data.covid19taskforce.com/data The global view below is complemented by country-specific dashboards here.

World Bank Vaccine Operations Portal

Milestones :: Perspectives :: Research

 

World Bank Vaccine Operations Portal
https://www.worldbank.org/en/who-we-are/news/coronavirus-covid19/world-bank-support-for-country-access-to-covid-19-vaccines
As of July 29, 2021, the World Bank approved operations to support vaccine rollout in 54 countries amounting to $4.6 billion. See the latest project financing, project documents and procurement information in the list below:

Countries receiving World Bank support for vaccines
As of July 29, 2021
This list of countries, project documents, and procurement notices and contracts will be updated as data becomes available.

COVID-19 Data Explorer: Global Humanitarian Operations

Milestones :: Perspectives :: Research

 

COVID Vaccines – OCHA:: HDX

COVID-19 Data Explorer: Global Humanitarian Operations
COVID-19 Vaccine Roll-out
Aug 21, 2021 | COVAX (WHO,GAVI,CEPI), UNDESA, Press Reports | DATA

 

Global COVID-19 Figures: 210M total confirmed cases; 4.4M total confirmed deaths
Global vaccines administered: 4.88B
Number of Countries: 26 [26]
COVAX Allocations (Number of Doses): 73M [73M week ago]
COVAX Delivered (Number of Doses): 53M [46M week ago]
Other Delivered (Number of Doses): 93M [61M week ago]
Total Delivered (Number of Doses): 150M [110M week ago]
Total Administered (Number of Doses): 110M [110M week ago]

Coronavirus [COVID-19] – WHO Public Health Emergency of International Concern (PHEIC)

Milestones :: Perspectives :: Research

::::::

 

Coronavirus [COVID-19] – WHO
Public Health Emergency of International Concern (PHEIC)
https://www.who.int/emergencies/diseases/novel-coronavirus-2019

 

Weekly Epidemiological and Operational updates
Last update: 13 Aug 2021
Confirmed cases :: 209 876 613 [205 338 159 week ago]
Confirmed deaths :: 4 400 284 [4 333 094 week ago]
Vaccine doses administered: 4 562 256 778 [4 428 168 759 week ago]

WHO Director-General’s opening remarks at the Member State Information Session on COVID-19 – 19 August 2021

Milestones :: Perspectives :: Research

 

19 August 2021 Speech
WHO Director-General’s opening remarks at the Member State Information Session on COVID-19 – 19 August 2021

18 August 2021 Speech
WHO Director-General’s opening remarks at the media briefing on COVID-19 – 18 August 2021
In Haiti, where the earthquake has killed more than 1,900 people, we are continuing to support the government and the people by all means possible during this difficult moment.
The people of Afghanistan are facing an enormous challenge.  We are particularly concerned about the health and wellbeing of women and girls.  Our staff remain in the country and committed to delivering health services to the most vulnerable.
This week, a new case of Ebola was identified in Côte d’Ivoire.  Thousands of doses of Ebola vaccines were sent from Guinea to Cote d’Ivoire and ring vaccination of high-risk contacts has started.
Just 10 countries have administered 75 per cent of all vaccine supply and low-income countries have vaccinated barely 2 per cent of their people.  I called for a temporary moratorium on boosters to help shift supply to those countries that that have not even been able to vaccinate their health workers and at-risk communities and are now experiencing major spikes.
Vaccine injustice is a shame on all humanity and if we don’t tackle it together, we will prolong the acute stage of this pandemic for years when it could be over in a matter of months.  When G20 health ministers meet on the 5th and 6th of September in Rome, I will call on them to consider the fragility of this historic moment and make a clear defining commitment to solidarity.
…At present, just 10 countries have administered 75 per cent of all vaccine supply and low-income countries have vaccinated barely 2 per cent of their people.

I called for a temporary moratorium on boosters to help shift supply to those countries that that have not even been able to vaccinate their health workers and at-risk communities and are now experiencing major spikes.

Last week, WHO brought together 2,000 experts from all around the world and debated the available data on boosters. What is clear is that it’s critical to get first shots into arms and protect the most vulnerable before boosters are rolled out.

 

The divide between the haves and have nots will only grow larger if manufacturers and leaders prioritise booster shots over supply to low- and middle-income countries. The virus is evolving and it is not in the best interests of leaders just to focus on narrow nationalistic goals when we live in an interconnected world and the virus is mutating quickly.

In fact, strong national leadership would be to fully commit to vaccine equity and global solidarity, which would save lives and slow variants down.

 

In this context, I was stunned by the news that J&J vaccines fill and finished in South Africa are leaving the continent and going to Europe, where virtually all adults have been offered vaccines at this point. 

We urge J&J to urgently prioritize distribution of their vaccines to Africa before considering supplies to rich countries that already have sufficient access…

 

::::::

Weekly operational update on COVID-19 – 16 August 2021
Overview
n this edition of the COVID-19 Weekly Operational Update, highlights of country-level actions and WHO support to countries include:
Facilitating procurement of 1.6 million antigen-detecting rapid diagnostic tests to strengthen COVID-19 diagnostic in Indonesia
The roll-out of Go.Data contact tracing tool in Ukraine
Donated COVID-19 vaccine doses by France arrive in Somalia
Community health at the center of COVID-19 vaccination in indigenous communities in Paraguay
Online learning opportunities to support hospital infection prevention and control committees in Azerbaijan
Progress on a subset of indicators from the SPRP 2021 Monitoring and Evaluation Framework
Updates on WHO’s financing to support countries in SPRP 2021 implementation and provision of critical supplies.

Weekly epidemiological update on COVID-19 – 17 August 2021
Overview
The global number of new cases has been increasing for the last 2 months with over 4.4 million cases reported in the past week (9 – 15 August 2021), bringing the cumulative number of globally to cases to over 206 million. This increasing trend is largely attributed to increases in the Western Pacific Region and the Region of the Americas which reported 14% and 8% increases respectively as compared to the previous week. Overall, the number of deaths reported remained similar with over 66 000 deaths this week, as compared to the previous week. While the African Region reported the largest percentage decrease in case and death incidence, 23% and 18% respectively, data from the weekend is incomplete which might lead to an overestimation of the percentage change. The Western Pacific and the Eastern Mediterranean Regions reported the highest proportionate increases in death incidence of 23% and 15% respectively over the last seven days.

In this edition, a special focus updates are provided on:
SARS-CoV-2 Variants of Concern (VOCs) Alpha, Beta, Gamma and Delta which includes updates on the geographic distribution of VOCs.
COVID-19 in Prisons

 

::::::

Call for experts to join Scientific Advisory Group for the Origins of Novel Pathogens
20 August 2021 News release
Issued on: 20 August Deadline: 10 September
The World Health Organization (WHO) today issued an open call for experts to serve as members of the new WHO Scientific Advisory Group for the Origins of Novel Pathogens (SAGO).

The SAGO will advise WHO on technical and scientific considerations regarding the origins of emerging and re-emerging pathogens of epidemic and pandemic potential, and will be composed of a wide range of experts acting in their personal capacity. SAGO will also guide WHO on next steps for understanding the SARS-CoV-2 origins.

There have been an increasing number of high threat pathogens emerging and re-emerging in recent years with, for example, SARS-CoV, MERS-CoV, Lassa, Marburg, Ebola, Nipah, avian influenza, the latest being SARS-CoV-2. There is a clear need for robust surveillance and early actions for rapid detection and mitigation efforts, as well as systematic processes to study the emergence of these pathogens and routes of transmission from their natural reservoirs to humans. This is critical to helping WHO, Member States and partner institutions to prepare for future spillover threats and to minimize the risk of a disease outbreak growing into a pandemic.

From SARS-CoV-2, which continues to wreak havoc around the world, to the next “Disease X”, this global framework to study the emergence of new and known high threat pathogens needs to be comprehensive and coordinated based on a One Health approach. It should also encompass biosafety and biosecurity. And it needs to be scientific, transparent, comprehensive, rapid and inclusive…

Functions of SAGO
…4. In the context of SARS-CoV-2 origins:
:: To provide the WHO Secretariat with an independent evaluation of all available scientific and
technical findings from global studies on the origins of SARS-CoV-2;
:: To advise the WHO Secretariat regarding developing, monitoring and supporting the
next series of studies into the origins of SARS-CoV-2, including rapid advice on WHO’s
operational plans to implement the next series of global studies into the origins of
SARS-CoV-2, as outlined in the ‘Joint WHO-China Global Study of Origins of SARS-
CoV-2: China Part’ report published on 30 March 2021 and advise on additional studies as
needed; and
5. To provide additional advice and support to WHO, as requested by the WHO SAGO Secretariat,
which may include participation in future WHO-international missions to study the origins of SARS-
CoV-2 or for other emerging pathogens.

…More information can be found on the Terms of Reference of the SAGO The SAGO will be multidisciplinary, with members who have a range of technical knowledge, field experience, skills and experience relevant to emerging and re-emerging pathogens. Up to 25 experts may be selected…

Status of COVID-19 Vaccines within WHO EUL/PQ evaluation process 19 August 2021

Milestones :: Perspectives :: Research

 

Status of COVID-19 Vaccines within WHO EUL/PQ evaluation process 19 August 2021
For 22 vaccine candidates, presents Manufacturer, Name of Vaccine, NRA of Record, Platform, EOI Accepted Status, Pre-submission Meeting Held Status, Dossier Accepted for Review, Status of Assessment; Anticipated/Completed Decision Date
[See full scale graphics at link above]

COVID Vaccine Developer/Manufacturer Announcements

Milestones :: Perspectives :: Research

 

COVID Vaccine Developer/Manufacturer Announcements
[relevant press releases/announcement from organizations from WHO EUL/PQ listing above]

 

AstraZeneca
Press Releases
AZD7442 PROVENT Phase III prophylaxis trial met primary endpoint in preventing COVID-19
20 August 2021
:: 77% reduced risk of developing symptomatic COVID-19
:: First long-acting antibody combination to prevent COVID-19
Positive high-level results from the PROVENT Phase III pre-exposure prophylaxis trial showed AstraZeneca’s AZD7442 achieved a statistically significant reduction in the incidence of symptomatic COVID-19, the trial’s primary endpoint.
AZD7442, a combination of two long-acting antibodies (LAAB), reduced the risk of developing symptomatic COVID-19 by 77% (95% confidence interval (CI): 46, 90), compared to placebo. The trial accrued 25 cases of symptomatic COVID-19 at the primary analysis…

BioCubaFarma – Cuba
Últimas Noticias – [Website not responding at inquiry; receiving 403=Forbidden message]

 

CanSinoBIO
News – [Website not responding at inquiry]

Clover Biopharmaceuticals – China
News – No new digest announcements identified

 

Curevac [Bayer Ag – Germany]
News
August 16, 2021
Second-Generation mRNA COVID-19 Vaccine Candidate, CV2CoV, Demonstrates Improved Immune Response and Protection in Preclinical Study
:: Preclinical study provides evidence for strongly improved immune responses with second-generation mRNA backbone jointly developed by CureVac and GSK compared to CureVac’s first-generation mRNA backbone
:: Data demonstrate high protective efficacy of second-generation lead candidate, CV2CoV, in animal model during SARS-CoV-2 challenge study
:: Neutralizing capacity of induced antibodies tested against a range of variants, including the Beta, Delta and Lambda variant

 

Gamaleya National Center
Latest News and Events – No new digest announcements identified [See Russia/RFID below]

IMBCAMS, China
Home – – [Website not responding at inquiry; receiving 502 Bad Gateway]

 

Janssen/JNJ
Press Releases
Statement on Boosting with the Johnson & Johnson COVID-19 Vaccine
NEW BRUNSWICK, N.J., August 18, 2021 — We are engaging with the U.S. FDA, CDC and other health authorities and will share new data shortly regarding boosting with the Johnson & Johnson COVID-19 vaccine.
In July, Johnson & Johnson shared data demonstrating that our single-shot COVID-19 vaccine generated strong, persistent immune activity against the rapidly spreading Delta variant and other highly prevalent SARS-CoV-2 viral variants. Interim results from a Phase 1/2a study published in the New England Journal of Medicine also showed that the durability of the immune response was strong, with no waning for at least eight months, the length of time that had been evaluated to date.
Ensuring long-term and durable protection against hospitalization and death are critical in curbing the COVID-19 pandemic.

 

Moderna
Press Releases
August 16, 2021
Moderna Announces Supply Agreement with Canada for Expanded Supply of Moderna’s COVID-19 Vaccine in 2022, in 2023 and in 2024

 

Novavax
Press Releases – No new digest announcements identified
Novavax Appoints Biopharmaceutical Veterans Jim Kelly as Chief Financial Officer and Nasir Egal, Ph.D., as Senior Vice President of Quality Assurance
Aug 16, 2021

 

Pfizer
Recent Press Releases
08.16.2021
Pfizer and BioNTech Announce Submission of Initial Data to U.S. FDA to Support Booster Dose of COVID-19 Vaccine
:: Phase 1 safety and immunogenicity data in individuals who received a third dose of the Pfizer-BioNTech vaccine (BNT162b2) show a favorable safety profile and robust immune responses
:: The booster dose elicited significantly higher neutralizing antibody titers against the initial SARS-CoV-2 virus (wild type), and the Beta and Delta variants, compared to the levels observed after the two-dose primary series
:: After the booster dose, neutralizing titers for variants were similar to wild type
:: Given the high levels of immune responses observed, a booster dose given within 6 to 12 months after the primary vaccination schedule may help maintain a high level of protection against COVID-19

 

Sanofi Pasteur
Press Releases – No new digest announcements identified

 

Serum Institute of India
NEWS & ANNOUNCEMENTS
SCHOTT and Serum Institute of India Announce Joint Venture for Pharmaceutical Packaging
Serum Institute of India (SII) acquires 50% stake of SCHOTT Kaisha to become SCHOTT’s joint venture partner and secure pharma packaging supply
17 August 2021

 

Sinopharm/WIBPBIBP
News – No new digest announcements identified

 

Sinovac
Press Releases – No new digest announcements identified

 

Vector State Research Centre of Viralogy and Biotechnology
Home – No new digest announcements identified

Zhifei Longcom, China
[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.]
[No website identified]

 

::::::

GSK
Press releases for media
16 August 2021
Second-Generation mRNA COVID-19 Vaccine Candidate, CV2CoV, Demonstrates Improved Immune Response and Protection in Preclinical Study
:: Preclinical study provides evidence for strongly improved immune responses with second-generation mRNA backbone jointly developed by CureVac and GSK compared to CureVac’s first-generation mRNA backbone
:: Data demonstrates high protective efficacy of second-generation lead candidate, CV2CoV, in animal model during SARS-CoV-2 challenge study
:: Neutralizing capacity of induced antibodies tested against a range of variants, including the Beta, Delta and Lambda variant

 

SK Biosciences
Press releases – No new digest announcements identified

Duke – Launch and Scale Speedometer

Milestones :: Perspectives :: Research

 

Duke – Launch and Scale Speedometer

The Race for Global COVID-19 Vaccine Equity
A flurry of nearly 200 COVID-19 vaccine candidates are moving forward through the development and clinical trials processes at unprecedented speed; more than ten candidates are already in Phase 3 large-scale trials and several have received emergency or limited authorization. Our team has aggregated and analyzed publicly available data to track the flow of procurement and manufacturing and better understand global equity challenges. We developed a data framework of relevant variables and conducted desk research of publicly available information to identify COVID vaccine candidates and status, deals and ongoing negotiations for procurement and manufacturing, COVID burden by country, and allocation and distribution plans. We have also conducted interviews with public officials in key countries to better understand the context and challenges facing vaccine allocation and distribution
[accessed 24 July 2021]
See our COVID Vaccine Purchases research
See our COVID Vaccine Manufacturing research
See our COVID Vaccine Donations & Exports research

Global Dashboard on COVID-19 Vaccine Equity

Milestones :: Perspectives :: Research

 

Global Dashboard on COVID-19 Vaccine Equity
The Dashboard is a joint initiative of UNDP, WHO and the University of Oxford with cooperation across the UN system, anchored in the SDG 3 Global Action Plan for Healthy Lives and Well-being for All.

Dashboard on Vaccine Equity [accessed 21 Aug 21]: https://data.undp.org/vaccine-equity/
See also visualization on Vaccine Access and Vaccine Affordability

Coronavirus (COVID-19) Vaccinations[Accessed 21 Aug 21]

Milestones :: Perspectives :: Research

 

Our World in Data
Coronavirus (COVID-19) Vaccinations[Accessed 21 Aug 21]
32.3% of the world population has received at least one dose of a COVID-19 vaccine, and 24.3% is fully vaccinated.
4.91 billion doses have been administered globally, and 34.96 million are now administered each day.
Only 1.4% of people in low-income countries have received at least one dose.

U.S.: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

Milestones :: Perspectives :: Research

 

U.S.: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

Joint Statement from HHS Public Health and Medical Experts on COVID-19 Booster Shots
August 18, 2021
Today, public health and medical experts from the U.S. Department of Health and Human Services (HHS) released the following statement on the Administration’s plan for COVID-19 booster shots for the American people.

The statement is attributable to Dr. Rochelle Walensky, Director of the Centers for Disease Control and Prevention (CDC); Dr. Janet Woodcock, Acting Commissioner, Food and Drug Administration (FDA); Dr. Vivek Murthy, U.S. Surgeon General; Dr. Francis Collins, Director of the National Institutes of Health (NIH); Dr. Anthony Fauci, Chief Medical Advisor to President Joe Biden and Director of the National Institute of Allergy and Infectious Diseases (NIAID); Dr. Rachel Levine, Assistant Secretary for Health; Dr. David Kessler, Chief Science Officer for the COVID-19 Response; and Dr. Marcella Nunez-Smith, Chair of the COVID-19 Health Equity Task Force:

“The COVID-19 vaccines authorized in the United States continue to be remarkably effective in reducing risk of severe disease, hospitalization, and death, even against the widely circulating Delta variant. Recognizing that many vaccines are associated with a reduction in protection over time, and acknowledging that additional vaccine doses could be needed to provide long lasting protection, we have been analyzing the scientific data closely from the United States and around the world to understand how long this protection will last and how we might maximize this protection. The available data make very clear that protection against SARS-CoV-2 infection begins to decrease over time following the initial doses of vaccination, and in association with the dominance of the Delta variant, we are starting to see evidence of reduced protection against mild and moderate disease. Based on our latest assessment, the current protection against severe disease, hospitalization, and death could diminish in the months ahead, especially among those who are at higher risk or were vaccinated during the earlier phases of the vaccination rollout. For that reason, we conclude that a booster shot will be needed to maximize vaccine-induced protection and prolong its durability.

“We have developed a plan to begin offering these booster shots this fall subject to FDA conducting an independent evaluation and determination of the safety and effectiveness of a third dose of the Pfizer and Moderna mRNA vaccines and CDC’s Advisory Committee on Immunization Practices (ACIP) issuing booster dose recommendations based on a thorough review of the evidence. We are prepared to offer booster shots for all Americans beginning the week of September 20 and starting 8 months after an individual’s second dose. At that time, the individuals who were fully vaccinated earliest in the vaccination rollout, including many health care providers, nursing home residents, and other seniors, will likely be eligible for a booster. We would also begin efforts to deliver booster shots directly to residents of long-term care facilities at that time, given the distribution of vaccines to this population early in the vaccine rollout and the continued increased risk that COVID-19 poses to them.

“We also anticipate booster shots will likely be needed for people who received the Johnson & Johnson (J&J) vaccine. Administration of the J&J vaccine did not begin in the U.S. until March 2021, and we expect more data on J&J in the next few weeks. With those data in hand, we will keep the public informed with a timely plan for J&J booster shots as well.

“Our top priority remains staying ahead of the virus and protecting the American people from COVID-19 with safe, effective, and long-lasting vaccines especially in the context of a constantly changing virus and epidemiologic landscape. We will continue to follow the science on a daily basis, and we are prepared to modify this plan should new data emerge that requires it.

 

“We also want to emphasize the ongoing urgency of vaccinating the unvaccinated in the U.S. and around the world. Nearly all the cases of severe disease, hospitalization, and death continue to occur among those not yet vaccinated at all. We will continue to ramp up efforts to increase vaccinations here at home and to ensure people have accurate information about vaccines from trusted sources. We will also continue to expand our efforts to increase the supply of vaccines for other countries, building further on the more than 600 million doses we have already committed to donate globally.”

::::::

 

Editor’s Note:
We assess [1] the announcement of a plan as above to provide booster doses of COVID vaccines with an established start date ̶ before FDA action and before a CDC decision to accept a supporting recommendation from an ACIP meeting not yet held, and [2] concluding the announcement of such a plan by referencing continuing but unspecified efforts “to increase the supply of vacancies for other countries” to be incongruous.

 

::::::

Vaccines and Related Biological Products Advisory Committee– FDA
:: No meetings scheduled

 

::::::

White House [U.S.]
Briefing Room – Selected Major COVID Announcements
Remarks by President Biden on Fighting the COVID-⁠19 Pandemic
August 18, 2021 • Speeches and Remarks

Memorandum on Ensuring a Safe Return to In-Person School for the Nation’s Children
August 18, 2021 • Presidential Actions

FACT SHEET: President Biden to Announce New Actions to Protect Americans from COVID-⁠19 and Help State and Local Leaders Fight the Virus
August 18, 2021 • Statements and Releases
…Today the President will highlight the following actions:
Planning to Offer COVID-19 Booster Shots Starting the Week of September 20:
Today, public health and medical experts from the U.S. Department of Health and Human Services (HHS) announced a plan for administering booster shots later this fall, pending final Food and Drug Administration (FDA) evaluation and recommendations from the Centers for Disease Control and Prevention’s (CDC’s) Advisory Committee on Immunization Practices (ACIP). Under this plan, a booster would be administered, eight months after an individual’s second dose, beginning the week of September 20—at which point those individuals who were fully vaccinated earliest in the vaccination rollout will be eligible, including many health care providers, nursing home residents, and other seniors…We will also continue to expand our efforts to send vaccines to other countries, building on the more than 600 million doses we have already committed to donate globally…

Press Briefing by White House COVID-⁠19 Response Team and Public Health Officials
August 18, 2021 • Press Briefings

Europe: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

Milestones :: Perspectives :: Research

 

Europe: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

 

European Medicines Agency
News & Press Releases
News: EMA starts evaluating use of RoActemra in hospitalised adults with severe COVID-19 (new)
CHMP, Last updated: 16/08/2021

Artificial intelligence in medicine regulation
News 16/08/2021
The International Coalition of Medicines Regulatory Authorities (ICMRA) sets out recommendations to help regulators to address the challenges that the use of artificial intelligence (AI) poses for global medicines regulation, in a report published today.

 

::::::

European Centre for Disease Prevention and Control
https://www.ecdc.europa.eu/en
Latest Updates
News

 

::::::

Data as of 2021-08-14
https://vaccinetracker.ecdc.europa.eu/public/extensions/COVID-19/vaccine-tracker.html#uptake-tab

 

::::::

European Commission
https://ec.europa.eu/commission/presscorner/home/en
Press release 20 August 2021
Coronavirus: EU makes available additional humanitarian funding of €41 million to fight the pandemic
The EU will provide €41 million to help low and middle-income countries facing an unprecedented health, humanitarian and socio-economic crisis as the COVID-19 pandemic continues to persist, combined with the imbalance in the delivery of vaccines.

Press release 16 August 2021
Coronavirus: 13 European countries provide urgent assistance to Tunisia
To help Tunisia cope with the impact of the COVID-19 pandemic and the worrying health situation within the country, the European Union and its member states continue to mobilise emergency aid via the EU Civil Protection Mechanism.

Russia: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

Milestones :: Perspectives :: Research

 

Russia: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment
Russia: Sputnik V – “the first registered COVID-19 vaccine”
https://sputnikvaccine.com/newsroom/pressreleases/
Press Releases
A combination between AstraZeneca and the first component of Sputnik V vaccine (Sputnik Light) demonstrates high immunogenicity profile during the clinical study in Azerbaijan
Press release, 20.08.2021

Real-world data shows one shot Sputnik Light vaccine (the first component of the Sputnik V vaccine) has high safety and 93.5% efficacy against COVID during vaccination in Paraguay
Press release, 17.08.2021

India: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

Milestones :: Perspectives :: Research

 

India: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

 

Ministry of Health and Family Welfare
https://www.mohfw.gov.in/

Latest Updates
17.08.2021
Genomic Surveillance for SARS-CoV-2 In India: Indian SARS-CoV-2 Genomics Consortium (INSACOG) (Updated guidelines and SOPs)
… Indian SARS-CoV-2 Genomics Consortium (INSACOG) was established to expand Whole
Genome Sequencing of SARS-CoV-2 across the nation, aiding our understanding of how the virus
spreads and evolves. The Consortium had initially started with a network of ten regional genome
sequencing laboratories spread across the country and has now been expanded to currently include
28 INSACOG Genome Sequencing Laboratories (IGSLs) that are mapped to the States and UTs
for facilitating smooth flow of samples. The viral genome sequencing data generated by these
IGSLs is analysed by the respective centres and sent to the National Centre for Disease Control
(NCDC), Delhi for collation and integration…

 

Government of India – Press Information Bureau
Latest Press Releases

The approval for world’s first DNA based ‘ZyCov-D’ vaccine of Zydus Universe is a testimony to the innovative zeal of India’s scientists: PM
Posted on: 20 Aug 2021
The Prime Minister, Shri Narendra Modi has said that the approval for world’s first DNA based ‘ZyCov-D’ vaccine of is a testimony to the innovative zeal of India’s scientists.
In response to a tweet by CDSCO India Info, the Prime Minister said; “India is fighting COVID-19 with full vigour. The approval for world’s first DNA based ‘ZyCov-D’ vaccine of @ZydusUniverse is a testimony to the innovative zeal of India’s scientists. A momentous feat indeed.”
CDSCO_INDIA_INFO @CDSCO_INDIA_INF
Aug 20
After evaluation of interim Phase III clinical trial results in consultation with Subject Expert Committee, CDSCO has approved DNA COVID-19 vaccine (ZyCoV-D) of M/s Cadila Healthcare for restricted use in emergency situation in India for 12 years and above.

 

::::::

Zydus receives EUA from DCGI for ZyCoV-D, the only needle-free COVID vaccine in the world
:: World’s first Plasmid DNA Vaccine for COVID-19, ZyCoV-D will be administered in three
doses.
:: Apart from adults, for the first time adolescents in the age group of 12-18 years will take the
vaccine shot in India.
:: Safety, efficacy and immunogenicity of the vaccine is well established.
:: Company begins stockpiling of the vaccine.

Ahmedabad, August 20, 2021,
Zydus Cadila today announced that the company has received the Emergency Use Authorization (EUA) from the Drug Controller General of India (DCGI) for ZyCoV-D the world’s first Plasmid DNA Vaccine for COVID-19. ZyCoV-D is a three dose vaccine which will be administered first on day zero, day 28th and then on the 56th day. With this approval, India now has its first COVID-19 vaccine for the adolescents in the 12-18 age group, besides the adult population. ZyCoV-D, is a needle-free vaccine administered using The PharmaJet® a needle free applicator, which ensures painless intradermal vaccine delivery.

This is for the first time that a technologically advanced vaccine has been successfully developed on the Plasmid DNA platform for human use. The platform because of its rapid plug and play technology can be easily adapted to deal with mutations in the virus, such as those already occurring. The company plans to manufacture 10-12 crore doses of ZyCoV-D annually.

Speaking on this development, Mr. Pankaj R. Patel, Chairman, Cadila Healthcare Ltd., said “This is a historic milestone with ZyCoV-D, a product of Indian innovation becoming the world’s first DNA vaccine being offered for human use and supporting the world’s largest immunization drive. We are particularly happy that our vaccine will contribute to this fight against COVID-19 and enable the country to vaccinate a larger population especially in the age group of 12-18 years. I would like to thank all the researchers, clinical trial investigators, volunteers and the regulators who have supported this endeavour.”

The company also plans to seek approval for the two dose regimen of the vaccine. The main advantage of DNA vaccines is their ability to stimulate both the humoral and cellular arms of the adaptive immune system. They are a valuable form of antigen-specific immunotherapy, as they are safe, stable and can be easily produced. Zydus acknowledges the support of National Biopharma Mission, BIRAC, Department of Biotechnology, Govt of India, National Institute of Virology, Indian Council of Medical Research and PharmaJet® in the development of ZyCoV-D vaccine…

 

::::::

Indian Council for Medical Research (ICMR)
https://www.icmr.gov.in/media.html
Press Releases
India achieves milestone of 50 crores COVID-19 Sample Testing
19/08/2021

Polio Public Health Emergency of International Concern (PHEIC)

Emergencies

POLIO
Public Health Emergency of International Concern (PHEIC)

Polio this week as of 17 August 2021
:: The Global Polio Eradication Initiative (GPEI) is closely monitoring developments in Afghanistan. GPEI partners and staff are currently assessing immediate disruptions to polio eradication efforts and the delivery of other essential health services, to ensure continuity of surveillance and immunization activities while prioritizing the safety and security of staff and frontline health workers in the country. Read more

Summary of new WPV and cVDPV viruses this week (AFP cases and ES positives):
:: Pakistan: One WPV1 positive environmental sample
:: Madagascar: One cVDPV2 positive environmental sample
:: Nigeria: 26 cVDPV2 cases

 

::::::

Statement of the Twenty-Ninth Polio IHR Emergency Committee
20 August 2021
The twenty-ninth meeting of the Emergency Committee under the International Health Regulations (2005) (IHR) on the international spread of poliovirus was convened by the WHO Director-General on 4 August 2021 with committee members and advisers attending via video conference, supported by the WHO Secretariat.  The Emergency Committee reviewed the data on wild poliovirus (WPV1) and circulating vaccine derived polioviruses (cVDPV).  The following IHR States Parties provided an update at the video conference on the current situation in their respective countries: Afghanistan, China, Democratic Republic of the Congo, Egypt, Madagascar, Nigeria, Pakistan and Uganda.,,

Conclusion
Although heartened by the apparent progress, the Committee unanimously agreed that the risk of international spread of poliovirus remains a Public Health Emergency of International Concern (PHEIC) and recommended the extension of Temporary Recommendations for a further three months.  The Committee recognizes the concerns regarding the lengthy duration of the polio PHEIC, but concludes that the current situation remains risky, with clear ongoing risk of international spread and ongoing need for coordinated international responses. The Committee also recognised that the ongoing COVID-19 pandemic may have an adverse impact on polio surveillance and on immunisation activities, as will the gradual withdrawal of polio funds from some of the affected countries…

… Additional considerations
The Committee welcomed the substantial progress that has been made but warned that the situation in Afghanistan risked a rapid reversal of progress.  The Committee urged the polio programme to continue to discuss with all parties involved to ensure every missed child in inaccessible areas be quickly brought up to date with vaccines to avoid a sudden surge in cases, particularly as the high season commences. The Committee also urged donors and partners to continue their support, noting the beneficial use of polio assets during the pandemic and that a critical juncture had been reached:  decreasing funding by governments, partly as a result of the pandemic, risked all the hard won gains being lost.

The Committee also welcomed the roll-out of novel OPV2 but was concerned to hear of delays in outbreak response, in some cases as countries preferred to wait for novel OPV2.  Polio outbreaks should continue to be met with a suitable sense of urgency, and response time generally needed to be reduced.  The Committee requested the polio programme to continue to assist countries to mount an emergency response with whichever vaccine formulation was available.
The Committee also warned of the ongoing effects of COVID-19, particularly on routine immunization, and possible future disruptions of supply and delivery of vaccines.  COVID-19 is likely to continue to have negative effects on all health programs and systems for some time to come, so the polio programme must continue to adjust its response on an ongoing basis to get over the remaining hurdles.

Based on the current situation regarding WPV1 and cVDPV, and the reports provided by affected countries, the Director-General accepted the Committee’s assessment and on 10 August 2021 determined that the situation relating to poliovirus continues to constitute a PHEIC, with respect to WPV1 and cVDPV.  The Director-General endorsed the Committee’s recommendations for countries meeting the definition for ‘States infected with WPV1, cVDPV1 or cVDPV3 with potential risk for international spread’, ‘States infected with cVDPV2 with potential risk for international spread’ and for ‘States no longer infected by WPV1 or cVDPV, but which remain vulnerable to re-infection by WPV or cVDPV’ and extended the Temporary Recommendations under the IHR to reduce the risk of the international spread of poliovirus, effective 10 August 2021.

 

::::::
::::::

WHO/OCHA Emergencies

 

Editor’s Note:
WHO has apparently reorganized and fundamentally shifted how it judges and tracks “emergencies”. We found no announcement of descriptive information to share and present the webpage structure as encountered below. Obviously, the dates associated with some of these emergencies suggest that this is an archival platform as well as a current emergencies resource.

Health emergencies list – WHO
“The health emergencies list details the disease outbreaks, disasters and humanitarian crises where WHO plays an essential role in supporting countries to respond to and recover from emergencies with public health consequences.”

Crisis in Tigray, Ethiopia [Last apparent update: 5 Aug 2021]

 

Ebola outbreak, Democratic Republic of the Congo, 2021
:: 17 August 2021 News release Cote d’Ivoire starts Ebola vaccination of frontline workers

Ebola outbreak outbreak, N’Zerekore, Guinea, 2021
:: 17 August 2021 News release Cote d’Ivoire starts Ebola vaccination of frontline workers

Coronavirus disease (COVID-19) pandemic [See COVID above]

 

Ebola outbreak, Equateur Province, Democratic Republic of the Congo, 2020
:: 17 August 2021 News release Cote d’Ivoire starts Ebola vaccination of frontline workers

Ebola outbreak, North Kivu, Ituri, Democratic Republic of the Congo, 2018 – 2020
:: 17 August 2021 News release Cote d’Ivoire starts Ebola vaccination of frontline workers

Ebola outbreak, Democratic Republic of the Congo, 2018 [Last apparent update: 24 July 2018]

Yemen crisis [Last apparent update: 12 February 2021]

Syria crisis [Last apparent update: 18 June 2021]

Somalia crisis [Last apparent update: 24 March 2018]

Nigeria crisis [Last apparent update: 9 May 2018]

Ebola outbreak, Democratic Republic of the Congo, 2017 [Last apparent update: 3 May 2021]
:: 17 August 2021 News release Cote d’Ivoire starts Ebola vaccination of frontline workers

Zika virus disease outbreak, 2015-2016 [Last apparent update: 24 Jan 2020]

 

Ebola outbreak: West Africa, 2014-2016
:: 17 August 2021 News release Cote d’Ivoire starts Ebola vaccination of frontline workers

Iraq crisis [Last apparent update: 9 Jan 2008]

South Sudan crisis [Last apparent update: 23 Sep 2020]

Avian influenza A (H7N9) virus outbreak [Last apparent update: 21 May 2021]

Middle East respiratory syndrome (MERS-CoV) outbreak [Last apparent update: 8 July 2019]

Influenza A (H1N1) virus, 2009-2010 pandemic [Last apparent update: 10 Aug 2010]

 

::::::

UN OCHA – Current Emergencies
Current Corporate Emergencies
Northern Ethiopia
Ethiopia Humanitarian Bulletin Issue #11 2 – 16 August 2021

 

::::::
::::::

WHO & Regional Offices [to 21 Aug 21]

WHO & Regional Offices [to 21 Aug 21]
https://www.who.int/
News
20 August 2021
Statement
Statement of the Twenty-Ninth Polio IHR Emergency Committee
[See Polio above for detail]

20 August 2021
News release
Call for experts to join Scientific Advisory Group for the Origins of Novel Pathogens
[See COVID above for detail]

19 August 2021
Joint News Release
Bucharest, Cairo, Córdoba, Dublin, Greater Manchester, and Warsaw Join Bloomberg Philanthropies’ Partnership for Healthy Cities

19 August 2021
Statement
Statement by Principals of the Inter-Agency Standing Committee (IASC) on Afghanistan

18 August 2021
Statement
Joint Statement from Unitaid and the World Health Organization (on behalf of the Access to COVID-19 Tools Accelerator) regarding availability of tocilizumab

18 August 2021
Departmental news
Social Listening: Finding the Signal Through the Noise

18 August 2021
Departmental news
New WHO Publication: Infodemic Signal Detection During the COVID-19 Pandemic

17 August 2021
News release
Cote d’Ivoire starts Ebola vaccination of frontline workers

16 August 2021
News release
ACT-Accelerator launches urgent US$ 7.7 billion appeal to stem surge of dangerous variants and save lives everywhere
[See COVID above for detail]

16 August 2021
Medical product alert
Medical Product Alert N°5/2021: Falsified COVISHIELD vaccine

16 August 2021
Departmental news
Neglected tropical diseases: enhancing safe treatment for more than 1 billion people annually

14 August 2021
News release
PAHO deploys experts to support Haiti during earthquake aftermath

14 August 2021
News release
Cote d’Ivoire declares first Ebola outbreak in more than 25 years

::::::

 

WHO Regional Offices
Selected Press Releases, Announcements
WHO African Region AFRO
:: WHO support to countries rolling out multiple COVID-19 vaccines 19 August 2021
With 620 million COVID-19 vaccine doses set to arrive in Africa through COVAX alone by the end of 2021, African countries are set to roll out a range of different vaccines, each with their own unique storage, transport and administration requirements.
:: Meet team WHO: Dr Gilson Paluku, Immunization Officer 19 August 2021
A medical doctor with experience in over 15 countries in Africa and the Americas, Dr Paluku was Chief Medical Officer for North Kivu province in his native Democratic Republic of Congo (DRC) before joining the World Health Organization (WHO) back in 2001.
:: Togo vaccinates over 90% of health workers against COVID-19 19 August 2021
:: Learning from Botswana’s COVID-19 vaccine rollout 19 August 2021
Africa’s largest-ever vaccination drive is well underway.52 African countries are rolling out COVID-19 vaccines and over 73 million doses have been administered on the continent.

WHO Region of the Americas PAHO
No new digest content identified

WHO South-East Asia Region SEARO
No new digest content identified

WHO European Region EURO
No new digest content identified

WHO Eastern Mediterranean Region EMRO
:: Statement on Afghanistan by Dr Ahmed Al-Mandhari, WHO Regional Director for the Eastern Mediterranean
:: Joint statement on the occasion of World Humanitarian Day 19 August 2021
:: More than 40 000 doses of AstraZeneca COVID-19 vaccine, donated by Malta, arrive in Libya 18 August 2021
:: Race against time to boost COVID-19 vaccine uptake in Somalia 17 August 2021
:: Egypt receives third batch of AstraZeneca vaccines through the COVAX Facility 16 August 2021

WHO Western Pacific Region
No new digest content identified

 

::::::

New WHO Publications [Selected]
https://www.who.int/publications/i

Using multidimensional poverty and vulnerability indices to inform equitable policies and interventions in health emergencies
17 August 2021 | Scientific brief
Overview
To prevent or mitigate the health equity impacts of health emergencies, or the health dimensions of humanitarian emergencies, analysts and decision-makers require an evidence-base to inform equitable planning, policy making, and interventions. In addition to several existing emergencies rapid assessment tools, multidimensional poverty and vulnerability indices (MPIs or MVIs) have been used for measurement, analyses, and policy guidance in several countries around the world.  This research brief provides an overview of the use of MPIs and MVIs in health emergencies, with the goal of sharing insights and lessons learned. This brief shares experiences from Afghanistan, Colombia, Honduras, Iraq, and select countries in southern Asia. This research brief will also inform national health authorities when looking for ways to reinforce health equity into their measurement approaches in their policies before, during and after a health emergency.
PDF: https://apps.who.int/iris/rest/bitstreams/1363839/retrieve

Africa CDC [to 21 Aug 21]

Africa CDC [to 21 Aug 21]
http://www.africacdc.org/
News
Press Releases
The Government of Republic of Côte d’Ivoire has declared a case of an Ebola Virus Disease in Abidjan
Addis Ababa, 14 August 2021- the Government of Republic of Côte d’Ivoire has declared the presence of a case of an Ebola virus disease (EVD) infection in the capital city of Abidjan. The case is 18-year-old Guinean girl who travelled from Labe in Guinea to Abidjan by road on 11August 2021 and hospitalized on the night of 12 August 2021 following a high-grade fever. On the 14th of August 2021, the Institute Pasteur in Cote d’Ivoire confirmed the infection to be EVD. The patient is currently in isolation and under the care of a Treatment Center for Highly Epidemic Diseases at the Treichville University Hospital.
More recently, on 19 June 2021, the Republic of Guinea declared over the EVD outbreak after four months of concerted effort.  However, further investigation will be conducted to trace back the relation between this case and the concluded outbreak…

China CDC http://www.chinacdc.cn/en/

China CDC http://www.chinacdc.cn/en/

National Health Commission of the People’s Republic of China [to 21 Aug 21]
http://en.nhc.gov.cn/
News
Aug 21: Daily briefing on novel coronavirus cases in China
On Aug 20, 31 provincial-level regions and the Xinjiang Production and Construction Corps on the Chinese mainland reported 20 new cases of confirmed infections

National Medical Products Administration – PRC [to 21 Aug 21]
http://english.nmpa.gov.cn/news.html
News
China administers cumulative 1.9b vaccine doses
2021-08-20
China had administered more than 1.9 billion COVID-19 vaccine doses as of Wednesday, the National Health Commission said on Aug 19.

CCDC Weekly – Weekly Reports: Current Volume (3)
2021-08-20 / No. 34
PDF of this issue
Preplanned Studies: Field Simulation of Aerosol Transmission of SARS-CoV-2 in a Special Building Layout — Guangdong Province, China, 2021
Methods and Applications: Modelling the Emerging COVID-19 Epidemic and Estimating Intervention Effectiveness — Taiwan, China, 2021
Methods and Applications: Vaccination Vehicles for COVID-19 Immunization — China, 2021
Notes from the Field: The First Case of COVID-19 by an A.27 Lineage Variant Detected in a Returning Employee — Sichuan Province, China, January 7, 2021
Commentary: Guangdong’s Study of the Effectiveness of China’s Inactivated Vaccines Against the SARS-CoV-2 B.1.617.2 (Delta) Variant